USING OR NOT USING PROGESTOGEN ESTROGEN THERAPY IN POSTMENOPAUSAL LONG. CONSENSUS OF THE INTERNATIONAL EXPERIENCE

• Autor: Soihet, Samoel
• Formato: artículo
• Fecha de Publicación: 2015
• Institución: Sociedad Peruana de Obstetricia y Ginecología
• Repositorio: Revista Peruana de Ginecología y Obstetricia
• Lenguaje: español
• OAI Identifier: oai:ojs.pkp.sfu.ca:article/577
• Enlace del recurso: http://51.222.106.123/index.php/RPGO/article/view/577
• Nivel de acceso: acceso abierto

Estrogen replacement in climacteric already reaches 55 years of use last decade speaks risk of endometrial cancer, which some researchers believe to be due to overdose or that patients were already carrying injuries undiagnosed before receiving estrogen. The use of progesterone as risk protection was introduced. While it is true that counteract the endometrial receptors, increases the risk of women by blocking the cardio protective action to alter the metabolism of high density cholesterol and carbohydrates, as well as bone decalcification. It is totally unnecessary in the hysterectomy. And not protect breast tissue. Given this controversy, an international committee of experts met in the field of menopause and concluded that progestins are not necessary for combination therapy in menopause and can cause major problems not manage them. Each physician must use estrogen or progestin simple form, as appropriate, individually, until further research reports on profits and risks are obtained.